Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of “Buy” from Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $14.20.

AMRX has been the subject of a number of analyst reports. Truist Financial lifted their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Barclays began coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price for the company. Finally, Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, March 6th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in Amneal Pharmaceuticals by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock worth $179,729,000 after acquiring an additional 403,582 shares during the last quarter. Rubric Capital Management LP raised its position in Amneal Pharmaceuticals by 5.3% in the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after purchasing an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Amneal Pharmaceuticals by 3.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock valued at $70,681,000 after purchasing an additional 177,906 shares during the last quarter. Morgan Stanley boosted its stake in Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its stake in Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock worth $35,333,000 after purchasing an additional 558,877 shares in the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $12.48 on Friday. The stock’s fifty day simple moving average is $13.48 and its 200 day simple moving average is $12.24. Amneal Pharmaceuticals has a one year low of $6.68 and a one year high of $15.42. The firm has a market cap of $3.93 billion, a price-to-earnings ratio of 54.26 and a beta of 1.32.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.